Table 2.

Hospital course of patients with COVID-19 who survived to discharge.

	No. (%)
	All patients survived to discharge	Patients with no ED visits or readmissions	Patients with ED treat and release	Patients readmitted
Total no.	310	284	10	16
Hospital course
Median (range) length of stay, days	5 (0–33)	5 (0–29)	6 (2–17)	6 (2–33)
Treatment
Antibiotics	224 (72.3)	205 (72.2)	7 (70)	12 (75)
New oxygen therapy	216 (69.7)	198 (69.7)	7 (70)	11 (68.8)
Hydroxychloroquine	81 (26.1)	73 (25.7)	1 (10)	7 (43.8)
Remdesivir	39 (12.6)	35 (12.3)	3 (30)	1 (6.3)
Other experimental treatmenta	7 (2.3)	6 (2.1)	1 (10)	0 (0)
Complications
ICU	67 (21.6)	64 (22.5)	1 (10)	2 (12.5)
Intubation	42 (13.5)	39 (13.7)	0 (0)	3 (18.8)
Sepsis	55 (17.7)	51 (18)	2 (20)	2 (12.5)
Renal
Electrolyte abnormalities	124 (40)	117 (41.2)	3 (30)	4 (25)
AKI	86 (27.7)	77 (27.2)	3 (30)	6 (37.5)
Cardiac
Atrial arrhythmia	15 (4.8)	15 (5.3)	0 (0)	0 (0)
Ventricular arrhythmia	5 (1.6)	5 (1.8)	0 (0)	0 (0)
Heart failure	1 (0.3)	1 (0.4)	0 (0)	0 (0)
Acute coronary syndrome	1 (0.3)	1 (0.4)	0 (0)	0 (0)
Neurologic
Delirium	27 (8.7)	24 (8.5)	0 (0)	3 (18.8)
CVA	3 (0.9)	3 (1.1)	0 (0)	0 (0)
Seizure	1 (0.3)	1 (0.4)	0 (0)	0 (0)
Infection
UTI	16 (5.2)	14 (4.9)	1 (10)	1 (6.3)
Wound	4 (1.3)	3 (1.1)	0 (0)	1 (6.3)
C. diff	2 (0.6)	2 (0.7)	0 (0)	0 (0)
Flu	1 (0.3)	1 (0.4)	0 (0)	0 (0)
DVT/PE	8 (2.6)	7 (2.5)	1 (10)	0 (0)

Abbreviations: ICU, intensive care unit; AKI, acute kidney injury; CVA, cerebral vascular accident; UTI, urinary tract infection; C. diff, Clostridium difficile infection; flu, influenza virus infection; DVT, deep vein thrombosis; PE, pulmonary embolus.

^aLopinavir/ritonavir, darunavir/cobicistat, sarilumab.